TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment - Université de Rennes Access content directly
Journal Articles Scientific Reports Year : 2015

TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment

Abstract

Lung cancer is a serious public health problem. Although there has been significant progress in chemotherapy, non-small cell lung cancer is still resistant to current treatments, primarily because of the slow rate of cell development. It is thus important to find new molecules directed against targets other than proliferation agents. Considering the high proportion of mutant proteins in tumor cells, and the high rate of mutation of the TP53 gene in all cancers, and in NSCLC in particular, this gene is a perfect target. Certain new molecules have been shown to restore the activity of mutated p53 protein, for example PRIMA-1, which reactivates the His273 mutant p53. In a previous study, we presented triazine A190, a molecule with a cytostatic activity that blocks cells in the G1 phase and induces apoptosis. Here, we show that A190 not only restores mutant p53 activity, but also induces an overexpression of the NEDD9 gene, leading to apoptotic death. These findings might offer hope for the development of new targeted therapies, specific to tumor cells, which spare healthy cells
Fichier principal
Vignette du fichier
TP53 transcription factor.pdf (1.16 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-01165439 , version 1 (29-06-2015)

Identifiers

Cite

Bénédicte Rousseau, Catherine Jacquot, Julie Le Palabe, Marine Malleter, Christophe Tomasoni, et al.. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment. Scientific Reports, 2015, 5 (1), pp.10356. ⟨10.1038/srep10356⟩. ⟨hal-01165439⟩
121 View
119 Download

Altmetric

Share

Gmail Facebook X LinkedIn More